Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

ABVC

ABVC BioPharma (ABVC)

ABVC BioPharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ABVC
DateTimeSourceHeadlineSymbolCompany
18/04/202423:25GlobeNewswire Inc.AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareNASDAQ:ABVCABVC BioPharma Inc
17/04/202423:00GlobeNewswire Inc.ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MNASDAQ:ABVCABVC BioPharma Inc
10/04/202422:30GlobeNewswire Inc.ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50MNASDAQ:ABVCABVC BioPharma Inc
26/03/202423:30GlobeNewswire Inc.ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60MNASDAQ:ABVCABVC BioPharma Inc
21/03/202423:30GlobeNewswire Inc.AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million DollarsNASDAQ:ABVCABVC BioPharma Inc
19/03/202423:30GlobeNewswire Inc.ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia MagazineNASDAQ:ABVCABVC BioPharma Inc
15/03/202400:30GlobeNewswire Inc.ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business UpdateNASDAQ:ABVCABVC BioPharma Inc
01/03/202408:32Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ABVCABVC BioPharma Inc
01/03/202408:31Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ABVCABVC BioPharma Inc
28/02/202400:30GlobeNewswire Inc.ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion DollarsNASDAQ:ABVCABVC BioPharma Inc
17/02/202409:04Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ABVCABVC BioPharma Inc
16/02/202400:30GlobeNewswire Inc.ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future RevenuesNASDAQ:ABVCABVC BioPharma Inc
14/02/202411:59Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ABVCABVC BioPharma Inc
13/02/202400:30GlobeNewswire Inc.ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)NASDAQ:ABVCABVC BioPharma Inc
10/02/202409:04Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ABVCABVC BioPharma Inc
09/02/202401:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABVCABVC BioPharma Inc
09/02/202401:17GlobeNewswire Inc.ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per ShareNASDAQ:ABVCABVC BioPharma Inc
18/01/202409:01Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ABVCABVC BioPharma Inc
18/01/202409:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABVCABVC BioPharma Inc
18/01/202408:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABVCABVC BioPharma Inc
13/01/202409:01Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ABVCABVC BioPharma Inc
03/01/202423:24GlobeNewswire Inc.ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing FeesNASDAQ:ABVCABVC BioPharma Inc
08/12/202300:30GlobeNewswire Inc.ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical StudyNASDAQ:ABVCABVC BioPharma Inc
06/12/202300:30GlobeNewswire Inc.ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical TrialsNASDAQ:ABVCABVC BioPharma Inc
22/11/202300:30GlobeNewswire Inc.ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion MarketNASDAQ:ABVCABVC BioPharma Inc
21/11/202300:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABVCABVC BioPharma Inc
18/11/202309:00Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ABVCABVC BioPharma Inc
18/11/202309:00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ABVCABVC BioPharma Inc
18/11/202309:00Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ABVCABVC BioPharma Inc
17/11/202302:05GlobeNewswire Inc.ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200MNASDAQ:ABVCABVC BioPharma Inc
 Showing the most relevant articles for your search:NASDAQ:ABVC